Biosimilars in inflammatory bowel disease: Cost savings are welcome but evidence supporting equivalence of biosimilar and originator drugs is currently limited

Gregory T Moore

doi:10.5694/mja16.00775

Biosimilars in inflammatory bowel disease: Cost savings are welcome but evidence supporting equivalence of biosimilar and originator drugs is currently limited

Gregory T Moore

Medicine Monash Health

Research output: Contribution to journal › Comment / Debate › Other › peer-review

1 Citation (Scopus)

Original language	English
Pages (from-to)	294-295
Number of pages	2
Journal	Medical Journal of Australia
Volume	205
Issue number	7
DOIs	https://doi.org/10.5694/mja16.00775
Publication status	Published - 3 Oct 2016

Access to Document

10.5694/mja16.00775

Link to publication in Scopus

Cite this

@article{60a9f2c5f09e4cafa879543dd944733e,

title = "Biosimilars in inflammatory bowel disease: Cost savings are welcome but evidence supporting equivalence of biosimilar and originator drugs is currently limited",

author = "Moore, {Gregory T}",

year = "2016",

month = oct,

day = "3",

doi = "10.5694/mja16.00775",

language = "English",

volume = "205",

pages = "294--295",

journal = "Medical Journal of Australia",

issn = "0025-729X",

publisher = "Wiley-Blackwell",

number = "7",

}

TY - JOUR

T1 - Biosimilars in inflammatory bowel disease

T2 - Cost savings are welcome but evidence supporting equivalence of biosimilar and originator drugs is currently limited

AU - Moore, Gregory T

PY - 2016/10/3

Y1 - 2016/10/3

UR - http://www.scopus.com/inward/record.url?scp=85016924779&partnerID=8YFLogxK

U2 - 10.5694/mja16.00775

DO - 10.5694/mja16.00775

M3 - Comment / Debate

C2 - 27681963

AN - SCOPUS:85016924779

VL - 205

SP - 294

EP - 295

JO - Medical Journal of Australia

JF - Medical Journal of Australia

SN - 0025-729X

IS - 7

ER -